TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01290978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuraPrep
Description: The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Study: NCT04242446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Study: NCT04178057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 3mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 5mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 7.5mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222 10mg/kg
Description: Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
Study: NCT03600675

Intervention type: OTHER
Intervention: No intervention element, observational study.
Description: No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.

Intervention type: OTHER
Intervention: No intervention element, observational study.
Description: No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
Study: NCT01177514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
Study: NCT02066402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tedizolid (BAY119-2631)
Description: 50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: 50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
Study: NCT03699995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confocal Microscopy
Description: Undergo confocal microscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Description: Undergo digital dermoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Procedure
Description: Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo punch biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shave Biopsy
Description: Undergo shave biopsy
Study: NCT03494569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given as per City of Hope Standard Operating Procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study: NCT02317055

Intervention type: OTHER
Group type: OTHER
Intervention: imaging

Intervention type: OTHER
Group type: OTHER
Intervention: imaging
Study: NCT03424590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearblue Connected Ovulation Test System
Description: Urinary LH test to predict ovulation
Study: NCT02696564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule per day for two weeks, followed by two capsules per day for 46 weeks
Study: NCT01995448

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: Residue of blood further to NFS.
Study: NCT00993239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant (TL32711)
Description: 30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
Study: NCT00286208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, misoprostol
Study: NCT03166475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedures
Description: All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedures
Description: All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedures
Description: All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
Study: NCT01819025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 face-to-face therapy session and a smartphone-app
Description: An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT, treatment as usual
Description: 10 sessions of face-to-face therapy, full behavioral activation
Study: NCT04396041

Intervention type: DEVICE
Intervention: Microvascular Plug (MVP)
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.

Intervention type: DEVICE
Intervention: Amplatzer Vascular Plug (AVP)
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.

Intervention type: DEVICE
Intervention: Detachable coils
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
Study: NCT02295566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Not required

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Not required
Study: NCT02105805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietetic group sessions
Description: Group sessions to improve dietary adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietetic group sessions
Description: Group sessions to improve dietary adherence
Study: NCT02766816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 1 study - BBio bOPV
Description: A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 1
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 2
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 3
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2 study - Licensed bOPV
Description: Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 1 study - Licensed bOPV
Description: A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
Study: NCT03863522

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration
Description: Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cancer Detection cartridge
Description: The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
Study: NCT03126864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 administered by vein on Days -5 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 administered by vein on Days -5 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 900 mg/m2 administered by vein on Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 900 mg/m2 administered by vein on Day -3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33-CAR-T Cell Infusion
Description: CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33-CAR-T Cell Infusion
Description: CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.
Study: NCT00787319

Intervention type: OTHER
Intervention: no intervention
Description: Outpatients with age-related macular degeneration (AMD)
Study: NCT01637701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PkEP
Description: Plasmakinetic enucleation of the prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-TURP
Description: Bipolar transurethral resection of the prostate
Study: NCT05038852

Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you learn relaxation skills.

Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you learn relaxation skills.
Study: NCT01873573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation
Description: Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation
Description: Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
Study: NCT04130542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: IV infusion once every 3 weeks (Q3W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: IV infusion once every 3 weeks (Q3W).
Study: NCT05038852

Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you increase your positive feelings, behaviors, and thoughts.

Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you increase your positive feelings, behaviors, and thoughts.
Study: NCT03324464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Executive Training: Working Memory
Description: Computerized working memory training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Central Executive Training: Inhibitory Control
Description: Computerized inhibitory control training
Study: NCT05040607

Intervention type: OTHER
Intervention: Data Collection
Description: The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~-Retrospective data of pulmonary function, respiratory muscle function, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device using tapered flow resistive loading and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength.

Intervention type: OTHER
Intervention: Data Collection
Description: -Retrospective data collection of pulmonary function, respiratory muscle function, exercise capacity, physical fitness, and activities of daily living (ADL).
Study: NCT01567332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil
Description: For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil
Description: For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions.
Study: NCT03987425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
Study: NCT01993459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (sodium chloride) 0,9%
Description: We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
Study: NCT02932059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory
Description: Metamemory evaluation using a sentence construction strategy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory
Description: Metamemory evaluation using a sentence construction strategy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory
Description: Metamemory evaluation using a sentence construction strategy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory
Description: Metamemory evaluation using a sentence construction strategy
Study: NCT00792103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: NP101 study patch 4 hour application
Study: NCT03715400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Virtual Reality Training
Description: Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
Study: NCT02640443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Description: 60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
Study: NCT00749125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
Study: NCT01920425

Intervention type: DEVICE
Group type: OTHER
Intervention: Kinesia HomeView
Description: Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.

Intervention type: DEVICE
Group type: OTHER
Intervention: Kinesia HomeView
Description: Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand-written diary
Description: Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand-written diary
Description: Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
Study: NCT04402463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation
Study: NCT02057484

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT04402463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapeutic
Description: The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments).
Study: NCT01756261

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients treated with EYLEA under practical manner for AMD.
Study: NCT04167995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula lacteal forte
Description: Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
Study: NCT04555096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 180 Minute IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 180 Minute IV Infusion